NORSTMas an upper airway “disinfectant”
SaNOtize has demonstrated the effectiveness of its NORSTM formulation in eradicating different types of viruses, including influenza and H1N1, and is working diligently to determine its efficacy for preventing and treating COVID-19 infections.
At present, SaNOtize:
- Completed a randomized, double-blind, placebo-controlled trial that evaluated 79 confirmed cases of COVID-19, with a 1:1 ration of placebo (saline) to NONS treatment. SaNOtize’s treatment for the prevention and early treatment of COVID-19 succeeded in reducing the log10 viral load in highly infected patients by 1.364 which corresponds to more than 95% in 24 hours, and by more than 99% within 72 hours. The majority of these patients had been infected with the UK variant.
- Has Completed a Health Canada approval multi-center, randomized, controlled, phase II safety and efficacy study (N=143) evaluating nitric oxide nasal spray (NONS) in combination with a lavage and gargle, for the prevention of COVID-19 in healthcare workers and individuals at risk of infection; Nobody from the treatment arm got infected and strong safety data was shown.
- Has confirmed that NORSTM is >99.9% effective against different types of coronaviruses (including SARS-CoV-2, the virus that causes COVID-19) in tests conducted by the independent Institute for Antiviral Research at Utah State University;
- Received an IND to allow a clinical trial in the US